Tc 99m tilmanocept

Drug Profile

Tc 99m tilmanocept

Alternative Names: Lymphoseek; NEO3-09; Tc 99m-diethylenetriamine pentaacetic acid mannosyl dextran; Tc 99m-DTPA-mannosyl dextran; Technetium Tc 99m tilmanocept; Tilmanocept

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of California, San Diego
  • Developer Maimonides Medical Center; National Cancer Institute (USA); Navidea Biopharmaceuticals; Norgine; University of California, San Diego
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Breast cancer; Head and neck cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
  • Phase II Cervical cancer; Kaposi's sarcoma
  • Phase I Cardiovascular disorders; Endometrial cancer; Liver metastases; Rheumatoid arthritis
  • Clinical Phase Unknown Colorectal cancer

Most Recent Events

  • 20 Sep 2017 Launched for Breast cancer (Diagnosis) in Italy (Intradermal)
  • 20 Sep 2017 Launched for Malignant melanoma (Diagnosis) in Italy (Intradermal)
  • 20 Sep 2017 Launched for Squamous cell cancer (Diagnosis) in Italy (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top